Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02185040 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT02185040 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 42 participants.
The verdict
NCT02185040, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus.
Interventions
- DRUG Placebo
- DRUG CC-220
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2014-09-16 |
| Est. Completion | 2018-09-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02185040
The ClinicalTrials.gov registry entry for NCT02185040 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02185040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02185040 about?
NCT02185040 is a clinical study titled "A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.". The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus.
What is the current status of trial NCT02185040?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2014-09-16. Estimated completion is 2018-09-25.
What interventions are being tested in trial NCT02185040?
The interventions under investigation include: Placebo (DRUG), CC-220 (DRUG).
Who is sponsoring clinical trial NCT02185040?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.